Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib plus camrelizumab for advanced hepatocellular carcinoma
ChiCTR2100050061Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of donafenib and camrelizumab in hepatocellular carcinoma (HCC) (2 cohorts), sponsored by Peking Union Medical College Hospital. Primary endpoint: Progression-free survival. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
donafenibcamrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100050061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050061.